A dual-marker detection method based on laser immunoturbidimetry
By constructing a joint sensing map based on the FP cavity, the problem that the existing laser immune turbidity method cannot achieve dual marker detection is solved, and rapid and high-sensitivity dual marker detection is achieved, which simplifies the operation process. And reduce the amount of reagents and samples.
Patent Information
- Application Number
- CN202211147433.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-19
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-09-19
AI Technical Summary
The existing laser immunoturbidity method cannot achieve fast and highly sensitive dual marker detection, and there are cumbersome pre-processing and high reagent dosage problems.
Using an optical microfluidic laser system based on FP cavity, through innovative improvements in sensing methods, a priori combined sensing map is constructed, and the concentration of the first and second antigens is directly detected using the integrated value of the optical microfluidic laser intensity to achieve rapid , high sensitivity dual marker detection.
It realizes high sensitivity dual marker detection within 25 minutes, which has the advantages of simple operation, clear process, less reagent dosage and sample size, and has universal applicability and strong specificity.
Smart Images

Figure CN115453110B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of biosensors, relates to disease marker detection, and specifically provides a dual-marker detection method based on laser immunoturbidimetry. Background Art
[0002] With the integration and development of medicine and biomolecular science, the detection of major disease markers has become an important part of disease diagnosis and treatment; and, as more and more disease markers are discovered and studied, the relationship between diseases and markers has gradually become clear. There is not a one-to-one correspondence between diseases and markers. Often, a disease has multiple markers. The development of the disease is often accompanied by the release and absorption of different markers, and the same marker may correspond to multiple diseases; therefore, the detection of a single disease marker can no longer meet the needs of effective diagnosis of the disease. In addition, by studying the representative markers of two different diseases, the mechanism of action between diseases can be studied. Therefore, the dual-marker detection method is of practical significance, especially the rapid and highly sensitive dual-marker detection method.
[0003] To meet this demand, enzyme-linked immunosorbent assay (ELISA), which is regarded as the gold standard, has also been widely used in marker detection. For example, the document "X.Wu., et al. "Optofluidic laser for dual-mode sensitive biomolecular detection with a large dynamic range." Nature Communications 2014, 5, 3779" discloses laser ELISA to achieve high-sensitivity marker detection, and the detection limit of interleukin-6 reaches 1fg / ml (38aM). However, this method requires cumbersome preliminary processing and relatively expensive labeling reagents, and the pretreatment time usually takes several hours. If ELISA is used in the dual-marker detection scheme, the requirements for preliminary processing are higher and the time is longer, which is not conducive to clinical and commercialization.
[0004] In contrast, immunoturbidimetry, as a label-free immunoassay method, has the advantages of simple operation and rapid detection, but its low detection sensitivity limits its application in marker detection. To address this problem, patent document CN202010528691.8 uses particle-enhanced immunoturbidimetry to amplify the signal and improve sensitivity. However, this method is still based on the light loss of a single transmission and cannot, in principle, provide a qualitative improvement in sensitivity. Introducing laser into immunoturbidimetry is an effective method. For example, patent document CN109490202A discloses an immunoturbidimetric analyzer based on optical microfluidic laser, which enhances the signal by laser and cavity to achieve highly sensitive and rapid protein molecule detection. Furthermore, the document "Yang, X., et al." Turbidimetric inhibition immunoassay revisited to enhance its sensitivity via an optofluidic laser." Biosensors and Bioelectronics 2019, 13160-66" demonstrates highly sensitive and rapid detection of immunoglobulin G, but this method only demonstrates one antigen detection and cannot achieve dual-marker combined detection. Summary of the invention
[0005] The purpose of the present invention is to address the problem that the existing laser immunoturbidimetry cannot realize dual-marker detection, and to propose a dual-marker detection method based on laser immunoturbidimetry. Based on laser immunoturbidimetry, through the innovative improvement of the sensing method, rapid and highly sensitive dual-marker detection is realized, and it has the advantages of simple operation, clear process, less reagent usage and sample volume, etc.
[0006] To achieve the above object, the technical solution adopted by the present invention is:
[0007] A dual-marker detection method based on laser immunoturbidimetry is implemented based on an optical microfluidic laser system of an FP cavity, characterized in that the dual-marker detection method specifically includes the following steps:
[0008] Step 1: prepare the solution to be tested;
[0009] First, a first antibody corresponding to a first antigen is added to the sample to be detected, and the sample is incubated at 37°C for 5 to 10 minutes. Then, a second antibody corresponding to a second antigen is added, and the sample is incubated at 37°C for 5 to 10 minutes. Finally, rhodamine 6G is added as a laser dye to form a solution to be detected.
[0010] Step 2: Use a pipette to beat the solution to be tested evenly and inject it into the microfluidic channel to measure the integral value of the optical microfluidic laser intensity;
[0011] Step 3: Substitute the optical microfluidic laser intensity integral value into the a priori known joint sensing spectrum to obtain the concentrations of the first antigen and the second antigen respectively; the joint sensing spectrum is:
[0012]
[0013] Among them, y1 and y2 are a priori selected constants; P1, P2, P3, Q1, Q2, and Q3 are a priori fitting parameters, all of which are constants; F is the integrated value of the optical microfluidic laser intensity, C1 is the first antigen concentration, and C2 is the second antigen concentration.
[0014] Furthermore, the calculation process of the joint sensing map is:
[0015] Set the first antigen concentration to (C 1,1 ,C 1,2 ,...,C 1,N ), the set of the second antigen concentration is (C 2,1 ,C 2,2 ,...,C 1,M );Fix the concentration of the first antigen as C 1,n , n=1,2,...,N, and set the concentration of the second antigen to (C 2,1 ,C 2,2 ,...,C 1,M ), and each concentration combination (C 1,n ,C 2,m ), the optical microfluidic laser intensity integral value under m=1,2,...,M; adjusting the concentration of the first antigen, repeating this process, and finally measuring each concentration combination (C 1,n ,C 2,m ), the integrated value of the optical microfluidic laser intensity when n = 1, 2, ..., N, m = 1, 2, ..., M;
[0016] At each first antigen concentration, the fitting function relationship of the optical microfluidic laser intensity integral value with respect to the second antigen concentration is obtained according to the measurement data:
[0017] F n (y) = K n y+B n ,y=lgC 2,m
[0018] Among them, K n , B n All represent fitting parameters;
[0019] Arbitrarily select two y values: y = y1, y = y2. Under y = y1, y = y2, according to the fitting optical microfluidic laser intensity integral value F n (y1), F n(y2), and we get F n (y1), F n (y2) The fitting function relationship about the first antigen concentration:
[0020] F n (y1)=P1x+Q1、F n (y2) = P2x + Q2, x = lgC 1,n
[0021] Then the prior fitting parameters P1, P2, Q1, Q2 are obtained;
[0022] According to the fitting parameter B n Get B n The fitting function relationship about the first antigen concentration is:
[0023] B n =P3x+Q3
[0024] Then the prior fitting parameters P3 and Q3 are obtained;
[0025] Finally, the combined sensing spectrum of the integrated value of the optical microfluidic laser intensity with respect to the first antigen concentration and the second antigen concentration is obtained:
[0026]
[0027] Wherein, F is the integrated value of the optical microfluidic laser intensity, C1 is the first antigen concentration, and C2 is the second antigen concentration.
[0028] Furthermore, in the solution to be detected, both the first antibody and the second antibody were kept in excess to ensure that the size and volume of the immune complex were positively correlated with the antigen concentration, and the rhodamine concentration was 0.16 mM.
[0029] Furthermore, the optical microfluidic laser system based on the FP cavity includes: an optical path module, an FP cavity module and a data acquisition module; wherein the optical path module includes: a pump laser source 1, a first reflector 2, a second reflector 3, an attenuation plate 4, a beam splitter 5, a convex lens 6 and a third reflector 7, wherein the pump laser source provides a pump laser, and the pump laser passes through the first reflector, the second reflector, the attenuation plate, the beam splitter, the convex lens and the third reflector in sequence along the optical path and is incident on the FP cavity module at an incident angle of 10°; the FP cavity module is composed of two square tubes 11 sandwiched by two high-reflection mirrors 9, any one of the square tubes is used as a microfluidic channel, and the two ends are connected to a hose 10, and the other square tube is used as a support tube, and the microfluidic channel is used to pass a sample to be tested; the data acquisition module includes: a probe 12, a spectrometer 13 and an energy meter 14, wherein the energy meter monitors the energy of the pump laser in real time through the beam splitter, and the probe is located directly above the FP cavity module to collect the spectrum, and the probe is connected to the spectrometer through an optical fiber.
[0030] Based on the above technical solution, the beneficial effects of the present invention are:
[0031] The present invention provides a dual-marker detection method based on laser immunoturbidimetry. From the basic working principle: for a mixed sample solution with two antigens, after adding an antibody corresponding to the first antigen, the laser intensity will decrease as the first antigen-antibody complex is generated, and after adding an antibody corresponding to the second antigen, the laser intensity will respond to the second antigen-antibody complex, which is manifested as a further decrease in intensity. The final laser intensity is characterized by an optical microfluidic laser intensity integral value. On this basis, the present invention creatively constructs an a priori joint sensing spectrum for the first antigen and the second antigen, brings the measured optical microfluidic laser intensity integral value into the a priori joint sensing spectrum, and directly obtains the concentrations of the first antigen and the second antigen, with high detection sensitivity, that is, high-sensitivity dual-marker detection is achieved. Moreover, the entire detection process is within 25 minutes, and the detection speed is extremely fast. At the same time, it has the advantages of simple operation, clear process, less reagent usage and sample volume, etc. In addition, the present invention has universal applicability, can be applied to different protein detections, and has strong specificity. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] Figure 1 It is a schematic diagram of the system structure of the dual-marker detection method based on laser immunoturbidimetry in the present invention.
[0033] Figure 2 It is a schematic diagram of the principle of the dual-marker detection method based on laser immunoturbidimetry in the present invention.
[0034] Figure 3 These are the measurement results of the optical microfluidic laser intensity integral values for cardiac troponin I (cTnI) and immunoglobulin G (IgG) in the embodiments of the present invention.
[0035] Figure 4 This is a combined sensing spectrum for cardiac troponin I (cTnI) and immunoglobulin G (IgG) in an embodiment of the present invention. DETAILED DESCRIPTION
[0036] In order to make the purpose, technical solutions and beneficial effects of the present invention more clearly understood, the present invention is further described in detail below with reference to the accompanying drawings and embodiments.
[0037] In response to the demand for dual-marker combined detection, this embodiment provides a rapid and highly sensitive dual-marker combined detection method based on laser immunoturbidimetry. The method is implemented based on an optical microfluidic laser system of an FP cavity. Figure 1As shown, it includes: an optical path module, an FP cavity module and a data acquisition module; wherein the optical path module includes: a pump laser source 1, a first reflector 2, a second reflector 3, an attenuation plate 4, a beam splitter 5, a convex lens 6 and a third reflector 7, the pump laser source provides a pump laser, and the pump laser passes through the first reflector, the second reflector, the attenuation plate, the beam splitter, the convex lens, and the third reflector in sequence along the optical path and is incident on the FP cavity module at an incident angle of 10°, the first reflector and the second reflector are used to raise the optical path, the attenuation plate is used to control the pump energy, and the convex lens It is used to realize the convergence of pump laser, and the third reflector is used to ensure the incident angle of pump laser; the FP cavity module is composed of two high-reflection mirrors 9 sandwiching two square tubes 11, any one of the square tubes is used as a microfluidic channel, and the two ends are connected to the hose 10, and the other square tube is used as a supporting tube, and the microfluidic channel is used to pass the sample to be tested; the data acquisition module includes: a probe 12, a spectrometer 13 and an energy meter 14, the energy meter monitors the energy of the pump laser in real time through a beam splitter, the probe is located directly above the FP cavity block to collect the spectrum, and the probe is connected to the spectrometer through an optical fiber.
[0038] The optical microfluidic laser system based on the FP cavity is as follows: Figure 2 As shown, the specific steps include:
[0039] Step 1: prepare the solution to be tested;
[0040] First, the first antibody corresponding to the first antigen is added to the sample to be detected, and incubated at 37°C for 15-10 minutes (to produce the antigen-antibody complex corresponding to the first antigen), then the second antibody corresponding to the second antigen is added, and incubated at 37°C for 5-10 minutes (to produce the antigen-antibody complex corresponding to the second antigen); finally, rhodamine 6G is added as a laser dye to form a solution to be detected; the added antibodies are kept in excess to ensure that the size and volume of the generated immune complex are positively correlated with the antigen concentration, and the concentration of rhodamine 6G is 0.16mM;
[0041] Step 2: Use a pipette to beat the solution to be tested evenly and inject it into the microfluidic channel to measure the integral value of the optical microfluidic laser intensity;
[0042] Step 3: Substitute the optical microfluidic laser intensity integral value into the a priori known joint sensing spectrum to obtain the concentrations of the first antigen and the second antigen respectively; the joint sensing spectrum is:
[0043]
[0044] Among them, y1 and y2 are a priori selected constants; P1, P2, P3, Q1, Q2, Q3 are a priori fitting parameters, all of which are constants; F is the integrated value of the optical microfluidic laser intensity, C1 is the first antigen concentration, and C2 is the second antigen concentration;
[0045] Furthermore, in terms of working principle, the calculation process of the above joint sensing map is:
[0046] Set the first antigen concentration to (C 1,1 ,C 1,2 ,...,C 1,N ), the set of the second antigen concentration is (C 2,1 ,C 2,2 ,...,C 1,M );Fix the concentration of the first antigen as C 1,n , n=1,2,...,N, and set the concentration of the second antigen to (C 2,1 ,C 2,2 ,...,C 1,M ), and each concentration combination (C 1,n ,C 2,m ), the optical microfluidic laser intensity integral value under m=1,2,...,M; adjusting the concentration of the first antigen, repeating this process, and finally obtaining each concentration combination (C 1,n ,C 2,m ), the integrated value of the optical microfluidic laser intensity when n = 1, 2, ..., N, m = 1, 2, ..., M;
[0047] According to the measured data, when the concentration of the first antigen is fixed, the fitting function relationship between the integral value of the optical microfluidic laser intensity and the concentration of the second antigen can be obtained:
[0048] F n (y) = K n y+B n (1)
[0049] y=lgC 2,m 、m=1,2,...,M (2)
[0050] For K in formula (1) n , K n Any two points on the sensing curve can be calculated, so if we choose any two y values: y=y1, y=y2, we get:
[0051] F n (y1)=K n y1+B n (3)
[0052] F n (y2) = Kn y2+B n (4)
[0053] Then, K n It is expressed as:
[0054]
[0055] Furthermore, for F in formula (5) n (y1) and F n (y2), that is, when the concentration of the second antigen is a fixed value (y = y1, y = y2), F n (y1) and F n (y2) (integral value of the optical microfluidic laser intensity) is only related to the first antigen concentration, so the fitting result is F n (y1), F n (y2) is a functional relationship of the first antigen concentration:
[0056] F n (y1)=P1x+Q1 (6)
[0057] F n (y2)=P2x+Q2 (7)
[0058] x=lgC 1,n 、n=1,2,...,N (8)
[0059] For B in formula (1) n , which means F n The intercept value, that is, B n The value of is only related to the concentration of the first antigen, so according to the test data, B can be fitted n Functional relationship about the concentration of the first antigen:
[0060] B n =P3x+Q3 (9)
[0061] Combining all the above equations, we can get the functional relationship between the integrated value of the optical microfluidic laser intensity and the first antigen concentration and the second antigen concentration:
[0062]
[0063] Wherein, y1 and y2 are pre-selected constants; P1, P2, P3, Q1, Q2, Q3 are the fitting parameter values in the functional relationship expressions in the above equations (6), (7), and (9), all of which are constants obtained by fitting the test data; F is the integral value of the optical microfluidic laser intensity, C1 is the first antigen concentration, and C2 is the second antigen concentration;
[0064] Based on this, the above functional relationship is directly used as the combined sensing spectrum of the optical microfluidic laser intensity integral value regarding the first antigen concentration and the second antigen concentration. For the solution to be detected, dual-marker combined detection of the first antigen and the second antigen can be achieved based on the combined sensing spectrum.
[0065] More specifically, in this embodiment, the concentration of the first antigen: troponin (cTnI) and the second antigen: immunoglobulin (IgG) are jointly detected; first, a joint sensing curve needs to be constructed, and the specific process is as follows:
[0066] First, the first antigen standard solution and the second antigen standard solution were diluted according to a 10-fold concentration gradient to obtain a series of first antigen concentration solutions (sample solution A) and second antigen concentration solutions (sample solution B); then, the solutions to be detected were prepared respectively: 10 μL of sample solution A and 4 μL of sample solution B were added to 225 μL of buffer and incubated at 37° C. for 5 minutes, then 12 μL of the first antibody was added and incubated at 37° C. for 10 minutes, then 12 μL of the second antibody was added and incubated at 37° C. for 10 minutes to obtain a composite antigen-antibody mixed solution, and finally 1.5 mM RH6G aqueous solution was added to the composite antigen-antibody mixed solution to obtain a solution to be detected, wherein the dye concentration was 0.16 mM;
[0067] Then, the above series of solutions to be tested were beaten evenly in turn and then injected into the microfluidic channel, and the corresponding optical microfluidic laser intensity integral values were measured respectively; during the measurement process, the light intensity and incident angle of the pump laser were kept unchanged, and the microfluidic channel was cleaned with ultrapure water before each solution to be tested was passed to prevent interference from the residual solution to be tested at the previous concentration;
[0068] Finally, according to the optical microfluidic laser intensity integral value measured under the a priori known first antigen concentration, second antigen concentration and their combination, data processing is performed to obtain the joint sensing map:
[0069] The concentrations of the first antigen were 26.55 fM, 265.5 fM, and 2655 fM, respectively, and the concentrations of the second antigen were 7.35 fM, 7.35×10 1 fM, 7.35×10 2 fM, 7.35×10 3 fM, 7.35×10 4 fM, 7.35×10 5 fM, respectively measured to obtain the integrated value of the optical microfluidic laser intensity as Figure 3 As shown, F1, F2 and F3 represent the first antigen concentrations of 26.55fM, 265.5fM and 2655fM, respectively, and are fitted as follows:
[0070] F1=-18162y+190837
[0071] F2=-15046y+157406
[0072] F3=-6035y+118021
[0073] Select y1=0、y2=0.887. When y1=0, then F n =B n , F n (y1), F n (y2) is linearly fitted with the concentration of the first antigen to obtain:
[0074] F n (y1=0)=B n =P1x+Q1=P3x+Q3=-33555x+234859
[0075] F n (y2=0.887)=P2x+Q2=-28881x+212584
[0076] That is: y1=0, y2=0.887, P1=P3=-33555, P2=-28881, Q1=Q3=234859, Q2=212584, and then a combined sensing spectrum is obtained; based on this combined sensing spectrum, the combined detection of the first antigen: troponin (cTnI) and the second antigen: immunoglobulin (IgG) concentration can be achieved.
[0077] Furthermore, in this embodiment, when the concentration of the first antigen is 26.55fM, 50fM, 100fM, 200fM, 265.5fM, 400fM, 800fM, 1600fM and 2655fM, the concentration range of the second antigen is within the actual measurement range (such as Figure 4 As shown in Figure 2), we further obtain the joint sensing map as Figure 4 As shown; wherein, L1 to L9 respectively represent the sensing curves of the second antigen with a first antigen concentration of 26.55fM, 50fM, 100fM, 200fM, 265.5fM, 400fM, 800fM, 1600fM, and 2655fM. It can be seen from the figure that each integral intensity value in the combined sensing spectrum uniquely corresponds to a group of first antigen and second antigen concentration values, that is, based on the combined sensing spectrum, high-sensitivity combined detection of the first antigen: troponin (cTnI) and the second antigen: immunoglobulin (IgG) concentration can be achieved, and the combined detection time is within 25 minutes.
[0078] The above description is only a specific implementation mode of the present invention. Any feature disclosed in this specification, unless otherwise stated, can be replaced by other alternative features that are equivalent or have similar purposes; all the disclosed features, or all the steps in the methods or processes, except for mutually exclusive features and / or steps, can be combined in any way.
Claims
1. A dual-marker detection method based on laser immunoturbidimetry, implemented by an optical microfluidic laser system based on a FP cavity, characterized in that: The dual marker detection method specifically comprises the following steps: Step 1: prepare the solution to be tested; First, a first antibody corresponding to a first antigen is added to the sample to be detected, and the sample is incubated at 37°C for 5 to 10 minutes. Then, a second antibody corresponding to a second antigen is added, and the sample is incubated at 37°C for 5 to 10 minutes. Finally, rhodamine 6G is added as a laser dye to form a solution to be detected. Step 2: Use a pipette to beat the solution to be tested evenly and inject it into the microfluidic channel to measure the integral value of the optical microfluidic laser intensity; Step 3: Substitute the optical microfluidic laser intensity integral value into the a priori known joint sensing spectrum to obtain the concentrations of the first antigen and the second antigen respectively; the joint sensing spectrum is: Among them, y1 and y2 are a priori selected constants; P1, P2, P3, Q1, Q2 and Q3 are all a priori fitting parameters, and they are all constants; F is the integrated value of the optical microfluidic laser intensity, C1 is the first antigen concentration, and C2 is the second antigen concentration.
2. The dual-marker detection method based on laser immunoturbidimetry according to claim 1, characterized in that: The prior calculation process of the joint sensor map is: Set the first antigen concentration to (C 1,1 ,C 1,2 ,...,C 1,N ), the set of the second antigen concentration is (C 2,1 ,C 2,2 ,...,C 2,M );Fix the concentration of the first antigen as C 1,n , and set the second antigen concentration to (C 2,1 ,C 2,2 ,...,C 2,M ), and each concentration combination (C 1,n ,C 2,m ), n=1,2,...,N, m=1,2,...,M; adjust the concentration of the first antigen, repeat this process, and finally measure each concentration combination (C 1,n ,C 2,m ) under the optical microfluidic laser intensity integral value; At each first antigen concentration, the fitting function relationship of the optical microfluidic laser intensity integral value with respect to the second antigen concentration is obtained according to the measurement data: F n (y)=K n y+B n ,y=lgC 2,m Among them, K n With B n All represent fitting parameters; Arbitrarily select two y values: y = y1 and y = y2, and according to the fitting optical microfluidic laser intensity integral value F n (y1) and F n (y2), and we get F n (y1) and F n (y2) The fitting function relationship about the first antigen concentration: F n (y1)=P1x+Q1,F n (y2)=P2x+Q2,x=lgC 1,n Then the prior fitting parameters P1, P2, Q1 and Q2 are obtained; According to the fitting parameter B n Get B n The fitting function relationship about the first antigen concentration is: <h2 style=";text-align:left;direction:ltr">B<h2 style=";text-align:left;direction:ltr"> n <h2 style=";text-align:left;direction:ltr"> =P3x+Q3 Then the prior fitting parameters P3 and Q3 are obtained; Finally, the combined sensing spectrum of the integrated value of the optical microfluidic laser intensity with respect to the first antigen concentration and the second antigen concentration is obtained:
3. The dual-marker detection method based on laser immunoturbidimetry according to claim 1, characterized in that: In the solution to be detected, the first antibody and the second antibody were kept in excess, and the concentration of rhodamine was 0.16 mM.
4. The dual-marker detection method based on laser immunoturbidimetry according to claim 1, characterized in that: The optical microfluidic laser system based on the FP cavity comprises: an optical path module, an FP cavity module and a data acquisition module; wherein the optical path module comprises: a pump laser source (1), a first reflector (2), a second reflector (3), an attenuation plate (4), a beam splitter (5), a convex lens (6) and a third reflector (7); the pump laser source provides a pump laser, and the pump laser passes through the first reflector, the second reflector, the attenuation plate, the beam splitter, the convex lens and the third reflector in sequence along the optical path and then enters the FP cavity at an incident angle of 10°. The FP cavity module is composed of two high-reflection mirrors (9) sandwiched between two square tubes (11), any one of the square tubes is used as a microfluidic channel and is connected to a hose (10) at both ends, and the other square tube is used as a support tube, and the microfluidic channel is used to pass the sample to be tested; the data acquisition module includes: a probe (12), a spectrometer (13) and an energy meter (14), the energy meter monitors the energy of the pump laser in real time through a beam splitter, the probe is located directly above the FP cavity module to collect the spectrum, and the probe is connected to the spectrometer through an optical fiber.
